Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN)

Citi analyst Yigal Nochomovitz maintained a Buy rating on Attovia Therapeutics (ATTO) with a $30 target, while Morgan Stanley's Chris Quintero reiterated a Buy on Navan (NAVN) with a $33 target. Both stocks have Strong Buy consensus ratings and significant upside potential according to analysts.

Original reporting
Published Sep 5, 2026, 10:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 7:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN) — source image
Decision brief

The 30-second read

$ATTOBullishMed
01

Why it matters

Analyst upgrades can prompt short‑term buying pressure, but without a catalyst the effect may be modest.

02

Market read

Positive analyst sentiment may nudge both stocks higher, though impact is limited to traders focused on rating changes.

03

What to watch

No new product, trial data, or earnings release accompanies the upgrades, so price may be driven more by sentiment than fundamentals.

Relevance 7/10Novelty 5/10Timing: yesterday

Background

The article aggregates recent analyst upgrades for two North American companies, providing price targets and rating consensus.

Company-level read

Ticker impact

$ATTOBullishMedium confidence
Context

Citi analyst Yigal Nochomovitz maintained a Buy rating and raised the price target to $30, indicating bullish sentiment.

Expected impact

Modest price appreciation expected over the next weeks.

Evidence & confidence

Analyst rating and target are new, but no fundamental catalyst.

$NAVNBullishMedium confidence
Context

Morgan Stanley analyst Chris Quintero reiterated a Buy rating with a $33 price target, suggesting continued optimism.

Expected impact

Small to moderate price gain in the near term.

Evidence & confidence

Analyst reaffirmation is fresh news but lacks a material event.

Market effects

Both firms are in high‑growth sectors (healthcare and technology) and may benefit from broader sector optimism.

North American market sentiment may be slightly lifted by the positive analyst coverage.

Limited to investors tracking US‑listed biotech and travel‑tech stocks.

Counterpoint

Analyst targets may be overly optimistic given recent price performance; downside risk if earnings miss expectations.

Key entities

  • Citi

    Provides coverage and rating for ATTO.

  • Morgan Stanley

    Provides coverage and rating for NAVN.

Related articles

$ATTOMed

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase

$ATTOMedAI 8/10

Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials

Attovia Therapeutics (ATTO) reported sustained itch relief in a small study for its drug ATTO-1310, with no serious adverse events related to the treatment. The company plans phase 2 trials with 300 patients in one study and 255 in another, aiming for quarterly maintenance dosing. Attovia expects data from a phase 1b study in 2027 and has a cash runway into 2030. The company is developing antibody-based treatments for immune-mediated and inflammatory diseases.

$ATTOHighAI 9/10

Attovia reports 12-week data from ATTO-1310 itch therapy trial

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week Phase 1b trial results for ATTO-1310, an anti-IL-31 therapy. In chronic pruritus patients, 82% of treated patients saw a 4-point reduction in itch versus 22% with placebo. In high-itch atopic dermatitis patients, 44% of treated patients achieved a 4-point reduction versus 75% with placebo. The drug was generally well-tolerated, with plans for Phase 2 trials in 2027.

$NAVNHighAI 8/10

Navan, Inc. Earnings Call Highlights AI

Navan, Inc. (NAVN) reported Q2 revenue of $233M, up 35% YoY, with gross booking volume surpassing $3B, up 45%. The company raised its FY2027 revenue guidance to $927M-$933M. Management highlighted strong customer satisfaction, enterprise sales growth, and AI-driven efficiencies. Free cash flow turned positive at $28M.